← Leaderboards
Mikael Karlsson
Rockefeller University
$1,356,393
Attributed
$2,712,785
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $576K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,712,785 · 1
By mechanism
R01$2,712,785 · 1
Top collaborators
- Jeffrey Victor Ravetch6 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Jeffrey Victor Ravetch$66,226,718
- Nina Bhardwaj$33,867,850
- Stylianos Bournazos$8,462,360
- Madhav V Dhodapkar$18,788,265
- David A. Knorr$636,027
Others in their field
Other Emerging Leaders on “Engineering”
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- John E West · University Of Texas At Austin$131,399,667
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Joy Williamson-Lott · University Of Washington$69,987,326
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$62,539,586
Research focus
EngineeringAntibody EngineeringDoseAnti-Cd40Antigen PresentationAntitumor ResponseAntibodiesAgonistBlocking AntibodiesCancer ImmunotherapyCancer TherapyCd8-Positive T-LymphocytesCell KillingCellsCheckpoint TherapyAntibody TherapyBindingClinical TreatmentClinical TrialsCombined Modality TherapyCtla4 GeneCytotoxic T-LymphocytesDesignEvaluation
Grant awards (6)
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$370,726
R01 · FY2025 · CA
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$171,731
R01 · FY2025 · CA
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$515,333
R01 · FY2024 · CA
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$531,608
R01 · FY2023 · CA
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$547,420
R01 · FY2022 · CA
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$575,967
R01 · FY2021 · CA